

Special Issue

Molecules at Play in Cancer

Message from the Guest Editor

Even with a wide range of incidence, cancer can occur in any part of the human body and spread to areas other than the originally affected organ. From genes to transcripts, proteins (enzymes included) and metabolites, a long list of molecular factors have been blamed for triggering the transformation of normal cells into cancer cells, many of them also being considered as actionable molecules for targeted therapies.

However, combinations of cancer risk factors including race, sex, age, medical history, diet, habits and exposure to stress, toxins and radiation make each human dynamic and unique, questioning the meaning of cancer biomarkers and the feasibility of “fit-for-all” treatments. Tumor heterogeneity further complicates the characterization of cancer subtypes and requires complex approaches to destroy most of the primary cancer clones at once. Contributing papers to this Special Issue will present recent progress in the molecular diagnosis and targeted therapy of any type of cancer, with emphasis on how to better personalize the treatment to fit patient characteristics.

Guest Editor

Prof. Dr. Dumitru Iacobas

Personalized Genomics Laboratory, Undergraduate Medical Academy,
Prairie View A&M University, Prairie View, TX 77446, USA

Deadline for manuscript submissions

closed (31 December 2022)



Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/101698

*Current Issues in Molecular
Biology*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cimb@mdpi.com

[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)





Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Molecular Medicine, University of Otago,
Christchurch 8140, New Zealand

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC, PubMed, Embase, CAPlus / SciFinder, FSTA, AGRIS, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.3 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and reviewer names are published annually in the journal.